S-1与紫杉醇联合用于晚期/复发性伴有腹膜转移的胃癌患者的可行性研究（OGSG0401）
[Combination of S-1 and paclitaxel for advanced/recurrent gastric cancer patients with peritoneal metastasis, feasibility study (OGSG0401)].
作者信息
Kimura Yutaka, Machida Hirohisa, Fujitani Kazumasa, Yamamoto Moritoshi, Tominaga Kazunari, Yano Hiroshi, Shimokawa Toshio, Takiuchi Hiroya, Tsujinaka Toshimasa, Furukawa Hiroshi
机构信息
Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG), NTT West Osaka Hospital, Japan.
出版信息
Gan To Kagaku Ryoho. 2010 Jan;37(1):151-5.
BACKGROUND
The standard therapy for gastric cancer with peritoneal metastasis has remained unclear.
PURPOSE
This prospective feasibility study was aimed to investigate the efficacy and safety of S-1 plus paclitaxel for advanced/recurrent gastric cancer patients with peritoneal metastasis able to take oral feeding.
PATIENTS AND METHODS
Seven patients were enrolled in this study. Paclitaxel 50mg/m2 was administered on days 1 and 8. S-1 was administered orally at 40 mg/m2 bid for 14 consecutive days, followed by a 1-week rest. Overall survival, the response rate and safety were examined for efficacy and tolerability.
RESULTS
The median survival time was 310 days. The response rate in five patients was 80. 0%. Grade 3 toxicity was observed in two patients. Combination chemotherapy of weekly paclitaxel and S-1 demonstrated efficacy and tolerable toxicity. This regimen will be one of the initial treatment options for unresectable or metastatic gastric cancer with peritoneal metastasis.
背景
胃癌伴腹膜转移的标准治疗方法仍不明确。
目的
本前瞻性可行性研究旨在探讨S-1联合紫杉醇对能够经口进食的晚期/复发性胃癌伴腹膜转移患者的疗效和安全性。
患者与方法
本研究纳入7例患者。第1天和第8天给予紫杉醇50mg/m²。S-1以40mg/m² bid口服，连续服用14天，随后休息1周。对总生存期、缓解率和安全性进行疗效和耐受性检查。
结果
中位生存时间为310天。5例患者的缓解率为80.0%。2例患者观察到3级毒性。每周紫杉醇和S-1的联合化疗显示出疗效且毒性可耐受。该方案将成为不可切除或转移性胃癌伴腹膜转移的初始治疗选择之一。
Zotero 插件